98%
921
2 minutes
20
The Molecular Characterization Initiative (MCI), a key effort of the NCI's Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children's Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. De-identified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies. This commentary outlines the MCI's development, key accomplishments to date, and its role in laying the foundation for standardized clinical diagnostics in pediatric oncology.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360469 | PMC |
http://dx.doi.org/10.1093/jnci/djaf214 | DOI Listing |
Turk J Pediatr
September 2025
Department of Pediatric Hematology, Faculty of Medicine, Dokuz Eylül University, İzmir, Türkiye.
Backround: Leukemia is the most common childhood malignancy and often presents with nonspecific symptoms, which may lead to delays in diagnosis. Early recognition of clinical signs and laboratory abnormalities is essential to ensure timely referral and improve outcomes. This study assesses the clinical and laboratory characteristics of pediatric patients with acute and relapsed leukemia, points out key considerations during diagnosis, and investigates potential factors contributing to delayed diagnosis.
View Article and Find Full Text PDFJCO Glob Oncol
May 2025
Department of Medical Oncology, Dr B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Purpose: Gender bias against girls may affect health-seeking behavior and outcomes of childhood cancer. This study aimed to study the nature and extent of gender bias in health care among caregivers of childhood patients with cancer and also in community.
Methods: This cross-sectional mixed-methods study was conducted in a tertiary cancer hospital and an urban community between July 2021 and July 2023.
J Natl Cancer Inst
September 2025
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States.
Background: Among childhood cancer survivors, germline rare variants in autosomal dominant cancer susceptibility genes (AD CSGs) could increase subsequent neoplasm (SNs) risks, but risks for rarer SNs and by age at onset are not well understood.
Methods: We pooled the Childhood Cancer Survivor Study and St Jude Lifetime Cohort (median follow-up = 29.7 years, range 7.
J Neurooncol
September 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA.
Purpose: Cranial irradiation is associated with health-related quality of life (HRQoL) deficits in childhood cancer survivors. We investigated the relationship between radiation dose to brain substructures and HRQoL in children with brain tumors treated with proton beam therapy (PBT).
Methods: Data were obtained from children in the Pediatric Proton/Photon Consortium Registry who received PBT for primary brain tumors between 2015 and 2021.
Pediatr Surg Int
September 2025
Pediatric Surgery Department, Fattouma Bourguiba University Hospital, Monastir, Tunisia.
Purpose: This meta-analysis compares thoracoscopic versus open thoracotomy repair of esophageal atresia with tracheoesophageal fistula (EA/TEF).
Methods: We systematically searched PubMed, Web of Science, Cochrane Library, and Scopus from inception to April 2025 for studies comparing thoracoscopic versus conventional thoracotomy approaches. Two independent reviewers screened studies, extracted data, and assessed risk of bias using appropriate tools.